



Universiteit  
Leiden  
The Netherlands

## **Discovery of FLT3 inhibitors for the treatment of acute myeloid leukemia**

Grimm, S.H.

### **Citation**

Grimm, S. H. (2019, February 20). *Discovery of FLT3 inhibitors for the treatment of acute myeloid leukemia*. Retrieved from <https://hdl.handle.net/1887/68880>

Version: Not Applicable (or Unknown)

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/68880>

**Note:** To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/68880> holds various files of this Leiden University dissertation.

**Author:** Grimm, S.H.

**Title:** Discovery of FLT3 inhibitors for the treatment of acute myeloid leukemia

**Issue Date:** 2019-02-20

## List of publications

### **The Development of a Modular Synthesis of Teraryl-Based $\alpha$ -Helix Mimetics as Potential Inhibitors of Protein–Protein Interactions**

Trobe, M.; Peters, M.; Grimm, S.; Breinbauer, R. *Synlett* **2014**, 25, 1202–1214.

### **Development of a Multiplexed Activity-Based Protein Profiling Assay to Evaluate Activity of Endocannabinoid Hydrolase Inhibitors**

Janssen, A. P. A.; van der Vliet, D.; Bakker, A. T.; Jiang, M.; Grimm, S. H.; Campiani, G.; Butini, S.; van der Stelt, M. *ACS Chem. Biol.* **2018**, 13, 2406–2413.

### **Drug Discovery Maps, a Machine Learning Model That Visualizes and Predicts Kinome–Inhibitor Interaction Landscapes**

Janssen, A. P. A.; Grimm, S. H.; Wijdeven, R. H. M.; Lenselink, E. B.; Neefjes, J.; van Boeckel, C. A. A.; van Westen, G. J. P.; van der Stelt, M. *J. Chem. Inf. Model.* **2018**, DOI: 10.1021/acs.jcim.8b00640.

### **Activity-Based Protein Profiling Identifies $\alpha$ -Ketoamides as Inhibitors for Phospholipase A2 Group XVI**

Zhou, J.; Mock, E. D.; Martella, A.; Kantae, V.; Di, X.; Burggraaff, L.; Baggelaar, M. P.; Al-Ayed, K.; Bakker, A.; Florea, B. I.; Grimm, S. H.; den Dulk, H.; Li, C. T.; Mulder, L.; Overkleeft, H. S.; Hankemeier, T.; van Westen, G. J. P.; van der Stelt, M. *ACS Chem. Biol.* **2019**, DOI: 10.1021/acscchembio.8b00969.

### **Comprehensive structure-activity-relationship of azaindoles as highly potent FLT3 inhibitors**

Grimm, S. H.; Gagestein, B.; Keijzer, J. F.; Liu, N.; Wijdeven, R. H.; Lenselink, E. B.; Tuin, A. W.; van den Nieuwendijk, A. M. C. H.; van Westen, G. J. P.; van Boeckel, C. A. A.; Overkleeft, H. S.; Neefjes, J.; van der Stelt, M. *Bioorg. Med. Chem.* **2019**, manuscript accepted.

## Curriculum Vitae

Sebastian Hans Grimm was born on June 22<sup>nd</sup> 1987 in Graz, Austria. He graduated high school in 2005 at the *Bundesgymnasium und Bundesrealgymnasium Gleisdorf* in Austria. From 2005 to 2006 he performed his *Zivildienst* as an emergency medical technician at the Austrian Red Cross. In 2006 he started his Bachelor of Chemistry at the University of Graz during which he spent a semester at the *Universidad de Burgos* in Spain as part of the Erasmus student exchange programme. His undergraduate studies were concluded with an internship at the Graz University of Technology, researching photosensitive resins.

In 2011 he started his Masters in Chemistry at the University of Graz. His studies were completed with an internship at the Graz University of Technology in the research group of prof. dr. Rolf Breinbauer. His Master thesis titled *Synthesis of 5-substitutedpyridine-3-boronic acids as building-blocks for teraryl-based  $\alpha$ -Helix mimetics* was completed in 2014.

In the same year he started his PhD research at Leiden University in the Bio-organic synthesis group under the supervision of prof. dr. H. S. Overkleeft. After a year he continued in the newly founded group Molecular Physiology, under the supervision of prof. dr. Mario van der Stelt. His research was further part of the Cancer Drug Discovery Initiative, a collaboration set up in between the Leiden Institute of Chemistry, the Pivot Park Screening Center in Oss and the Netherlands Cancer Institute and was later joined by the Leiden University Medical Centre. He presented part of his research as poster presentations at CHAINS in Veldhoven (2016 and 2017) and as an oral presentation at the SLAS conference Translating Research Ideas into Future Therapeutics in Leuven, Belgium (2016).